Mechanistic Clinical Trial of Colchicine in Patients With Peripheral Artery Disease

Exclusion Criteria

• •1. Use of colchicine or systemic anti-inflammatory medication (eg. tocilizumab) in the past 3 months
• •2. Allergy to colchicine
• •3. Presence of medication with drug-drug interaction
• •4. Acute limb ischemia requiring emergent intervention
• •5. Autoimmune/autoinflammatory disorders affecting blood vessels or with planned need for systemic anti-inflammatory medication
• •6. Recent (\<14 days) systemic infection requiring hospitalization or ongoing treatment with antimicrobials
• •7. History of persistent anemia, thrombocytopenia, or neutropenia requiring hematology/oncology treatment or felt to pose unacceptable risk to colchicine by the principal investigator
• •8. Pregnant or lactating women
• •9. History of uncontrolled diabetes or an A1C \>10% prior to the baseline visit
• •10. History of CrCl \< 30 mL/minute or eGFR \< 30mL/minute or end-stage renal disease ESRD on dialysis
• •11. History of liver disease or chronically-elevated (\>3 months) ALT/AST \> 3.0 x ULN
• •12. Claustrophobia